Format

Send to

Choose Destination
Am Fam Physician. 2005 Aug 15;72(4):655-62.

Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C.

Author information

1
St. Mary's Family Practice Residency, Grand Junction, Corlorado, USA. rayward1024@yahoo.com

Erratum in

  • Am Fam Physician. 2007 Mar 15;75(6):808.

Abstract

Hepatitis C virus is the most common chronic blood-borne infection in the United States. The advent of new treatment regimens using pegylated interferons in combination with ribavirin has led to improved sustained viral response rates for some genotypes in large multicenter trials. Advances in the management of side effects and toxicities have expanded the pool of treatable patients. A recent National Institutes of Health consensus conference recommended that all patients who have bridging hepatic fibrosis and moderate inflammation together with detectable viremia should receive treatment with pegylated interferon and ribavirin. Unfortunately, these medications are very expensive and have significant side effects. Hematologic toxicities include anemia and leukopenia. These can be managed with close monitoring, use of growth factors, or dose reductions. Depression also can be caused or exacerbated by these medicines and may require treatment with a selective serotonin reuptake inhibitor, comanagement with psychiatry, or cessation of pegylated interferon and ribavirin treatment. Contraception is imperative because ribavirin is highly teratogenic. Influenza-like symptoms of fatigue, nausea, and mild fevers can be helped by quality patient education and support including frequent office visits. Data from randomized controlled trials demonstrating improvements in long-term survival as a result of treatment are not yet available, but it appears that patients who have no detectable virus six months after treatment have a good chance of remaining virus free for at least five years.

PMID:
16127955
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for American Academy of Family Physicians
Loading ...
Support Center